Search for Clinical Trial Results
Lung Adenocarcinoma - 26 Studies Found
Status | Study |
Not yet recruiting |
Study Name: The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar Condition: Advanced Primary Lung Adenocarcinoma Date: 2012-03-21 Interventions: Drug: endostar Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous dr |
Recruiting |
Study Name: A+C in Metastatic Lung Adenocarcinoma Cancer Condition: Lung Adenocarcinoma Metastatic Date: 2016-10-24 Interventions: Drug: Crizotinib, bevacizumab Eligible patients with ALK translocation or ROS1 translocation or MET ampl |
Not yet recruiting |
Study Name: Retrospective Analysis of the Expression of the Neurotensin Receptor by Metastatic Lung Adenocarcinomas Condition: Metastatic Lung Adenocarcinomas Date: 2016-08-24 Interventions: Other: Non intervention. Observation Study |
Recruiting |
Study Name: Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma Condition: Lung Adenocarcinoma Date: 2016-09-08 Interventions: Other: biopsies The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western b |
Recruiting |
Study Name: Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas Condition: Stage IV Lung Adenocarcinoma Date: 2014-04-21 Interventions:
|
Completed |
Study Name: Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases Condition:
Date: 2012-04-11 Interventions:
|
Active, not recruiting |
Study Name: The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR Condition: Adenocarcinoma of Lung Date: 2015-07-07 Interventions:
|
Active, not recruiting |
Study Name: Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma Condition: Lung Adenocarcinoma Date: 2010-11-24 |
Recruiting |
Study Name: Tepotinib Phase II Study in Lung Adenocarcinoma Harbouring MET Exon 14 (METex14) Skipping Alterations Condition: Lung Adenocarcinoma Stage IIIB/IV Date: 2016-07-29 Interventions: Drug: tepotinib Subjects received 500 mg of tepotinib tablet once daily orally during each 21 day cycle |
Recruiting |
Study Name: Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma Condition: Adenocarcinoma of Lung Date: 2016-06-15 Interventions:
|